2913-97-5

Basic information

• Product Name: N-(2-Oxoethyl)phthalimide
• Synonyms: (1,3-DIOXO-1,3-DIHYDROISOINDOL-2-YL)ACETALDEHYDE;1,3-DIOXO-2-ISOINDOLINEACETALDEHYDE;2-(1,3-DIOXOISOINDOLIN-2-YL)ACETALDEHYDE;2-PHTHALIMIDOACETALDEHYDE;N-(2-OXOETHYL)PHTHALIMIDE;N-(FORMYLMETHYL)PHTHALIMIDE;n-(formylmethyl)-phthalimid;PHTHALIMIDOACETALDEHYDE
• CAS NO: 2913-97-5
• Molecular Formula: C₁₀H₇NO₃
• Molecular Weight: 189.17
• Product Categories: Aromatics Compounds;Aromatics;Cross Linking Reagents;Heterocycles;Miscellaneous Reagents
• Mol File: 2913-97-5.mol

Chemical Properties

• Melting Point: 116-118°C
• Boiling Point: 324.319 °C at 760 mmHg
• Flash Point: 151.476 °C
• Appearance: Off-white solid
• Density: 1.376 g/cm³
• Vapor Pressure: 0.000247mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly, Heated, Sonicated), Ethyl Acetate (Slightly)
• PKA: -2.45±0.20(Predicted)
• CAS DataBase Reference: N-(2-Oxoethyl)phthalimide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-Oxoethyl)phthalimide(2913-97-5)
• EPA Substance Registry System: N-(2-Oxoethyl)phthalimide(2913-97-5)

Safety Data

• RTECS: TI5125000
• HazardClass: IRRITANT
• Hazardous Substances Data: 2913-97-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-(2-Oxoethyl)phthalimide is used as a synthetic intermediate for the production of various organic compounds. Its application in this field is due to its reactivity and ability to form a wide range of derivatives, making it a versatile building block in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(2-Oxoethyl)phthalimide is used as a key component in the development of new drugs. Its unique chemical structure allows it to be incorporated into various drug candidates, potentially leading to the discovery of novel therapeutic agents with improved efficacy and safety profiles.
Used in Chemical Research:
N-(2-Oxoethyl)phthalimide is also utilized in chemical research as a model compound for studying various reaction mechanisms and exploring new synthetic routes. Its off-white solid form makes it suitable for various analytical techniques, contributing to the advancement of chemical knowledge and understanding.

InChI:InChI=1/C10H7NO3/c12-6-5-11-9(13)7-3-1-2-4-8(7)10(11)14/h1-4,6H,5H2

Upstream product

• 85-44-9 phthalic anhydride 

Downstream Products

• 74509-96-9 2,5-Dioxo-4-phenyl-6-phthalimido-3-hexancarbonsaeure-ethylester 
• 74509-94-7 1,3-Diphenyl-5-phthalimidopentan-1,4-dion 
• 184688-89-9 2-(2-{[(S)-1-(2-Hydroxy-phenyl)-2-(1H-imidazol-2-yl)-ethyl]-methyl-amino}-ethyl)-isoindole-1,3-dione 
• 74509-93-6 1-Phenyl-5-phthalimidopentan-1,4-dion 
• 81068-52-2 phthalimidoacetaldehyde 2,4-dinitrophenylhydrazone 
• 209793-11-3 (2R,3R)-2-((2R,4R)-2-Benzhydryl-4-phenyl-oxazolidin-3-yl)-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-3-hydroxy-butyric acid tert-butyl ester 
• 258501-34-7 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[[N-methyl-N-(2-phthalimidoethyl)amino]oxy]ethyl]-5-methyluridine 
• 877168-42-8 2-[2-(3-phenyl-piperidin-1-yl)-ethyl]-isoindole-1,3-dione 

Relevant articles and documents

Design, synthesis and structure - Activity relationship of phthalimides endowed with dual antiproliferative and immunomodulatory activities

Twenty-seven compounds showed dual anti-cancer and immunomodulatory activities.Series (6a-f) show perceptual inhibition range of 32.1-96.8 for SF-295 cell line.Compounds (6b) and (6f) show better inhibition profile of cancer cell lines than thl.The functionalization of series 3 to series 6 achieved better anti-cancer profile.

Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi

Chagas disease is a parasitic infection caused by protozoan Trypanosoma cruzi that affects approximately 6-7 million people worldwide. Benznidazole is the only drug approved for treatment during the acute and asymptomatic chronic phases; however, its efficacy during the symptomatic chronic phase is controversial. The present work reports the synthesis and anti-T. cruzi activities of a novel series of phthalimido-thiazoles. Some of these compounds showed potent inhibition of the trypomastigote form of the parasite at low cytotoxicity concentrations in spleen cells, and the resulting structure-activity relationships are discussed. We also showed that phthalimido-thiazoles induced ultrastructural alterations on morphology, flagellum shortening, chromatin condensation, mitochondria swelling, reservosomes alterations and endoplasmic reticulum dilation. Together, these data revealed, for the first time, a novel series of phthalimido-thiazoles-structure-based compounds with potential effects against T. cruzi and lead-like characteristics against Chagas disease.

HETEROCYCLIC COMPOUNDS AND USE THEREOF

Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease.

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly as NAMPT inhibitors. wherein, ring A, L1, L2, X1, X2, X3, Z, R1, R2, R3, R4, R5, m, n, p and q have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.

Synthesis of some analogues of (±)gelliusine F, (±)gelliusine E, and total synthesis of 2,2-di(6′-bromo-3′-indolyl)ethylamine

Synthesis of some analogues of indole based marine alkaloid (±)gelliusine F, (±)gelliusine E, and total synthesis of 2,2-di(6′-bromo-3′-indolyl)ethylamine are reported.

Direct organocatalytic asymmetric aldol reactions of α-amino aldehydes: Expedient syntheses of highly enantiomerically enriched anti-β-hydroxy-α-amino acids

(Chemical Equation Presented) A simple and efficient method for the synthesis of highly enantiomerically enriched β-hydroxy-α-amino acid derivatives has been developed. Direct asymmetric aldol reactions of a glycine aldehyde (aminoacetaldehyde) derivative have been performed under organocatalysis using L-proline or (S)-5-pyrrolidine-2-yl-1H-tetrazole. The reactions afforded anti-β-hydroxy-α-amino aldehydes in good yield with high diastereoselectivity (dr up to >100:1) and high enantioselectivity (up to >99.5% ee), which were easily transformed into β-hydroxy-α- amino acid derivatives.

Process for the oxidation of alcohols to aldehydes and ketones in the presence of nitroxyl compounds as catalysts

An alcohol is oxidized to an aldehyde or a ketone in the presence of a nitroxyl compound as catalyst, wherein the alcohol to be oxidized is contained in an organic liquid phase, and is reacted in the presence of a nitroxyl compound with an aqueous phase comprising an oxidant. The reaction is carried out continuously at a contact time of the phases of from 0.1 s to a maximum of 15 minutes, with intensive mixing of the phases. The process produces high yields with low quantities of other oxidation byproducts.